Effect of weight loss on proteinuria in adults with type 2 diabetes: A real-world study

被引:2
|
作者
Ren, Wenqian [1 ]
Gong, Yujia [1 ]
Zhen, Qin [1 ]
Gu, Liping [1 ]
Yang, Jiaying [1 ]
Kang, Mei [2 ]
Zhang, Aifang [1 ]
Shen, Tingting [1 ]
Wang, Yufan [1 ]
Liu, Fang [1 ,3 ]
Li, Na [1 ,3 ]
机构
[1] Shanghai Jiao Tong Univ, Sch Med, Shanghai Gen Hosp, Dept Endocrinol & Metab, Shanghai 200080, Peoples R China
[2] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Clin Med Res Ctr, Sch Med, Shanghai 200080, Peoples R China
[3] 100 Haining Rd, Shanghai 200080, Peoples R China
基金
中国国家自然科学基金;
关键词
Body weight; Proteinuria; Regression; Type; 2; diabetes; CHRONIC KIDNEY-DISEASE; BODY-MASS INDEX; RISK-FACTORS; OBESITY; PREVALENCE; MANAGEMENT;
D O I
10.1016/j.diabres.2023.111021
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims: To assess the impact of weight loss on proteinuria in patients with type 2 diabetes (T2DM) in real-world settings. Methods: A total of 1054 participants were categorized based on weight change from baseline to one-year followup: weight gain (>= 3%), stable weight, or weight loss (>= 3%). Proteinuria outcomes were defined as urinary albumin/creatinine ratio (UACR) progression (>= 30 % increase), UACR regression (>= 30 % reduction), or UACR stable. Ordered logistic regression analysis evaluated the relationship between weight loss and UACR regression. Results: Of the 1054 participants, 44.5 % were overweight, and 24.1 % were obese. Patients with obesity were at higher risk of developing proteinuria (OR, 1.783; 95 %CI, 1.195 to 2.659). Weight loss was associated with an 83.3 % increase in UACR regression compared to weight gain (OR, 1.833; 95 % CI, 1.262 to 2.663; P = 0.001). This association remained consistent across most subgroups and stronger in males (P for interaction = 0.023), with a 6 % UACR regression for every 1 kg weight loss (OR, 1.06; 95 % CI, 1.02 to 1.10; P = 0.003). Conclusions: Our real-world study reveals that weight reduction is associated with UACR regression in patients with T2DM, regardless of the approach used for weight management, and the association was much stronger in males.
引用
收藏
页数:6
相关论文
共 50 条
  • [21] Effect of Semaglutide on Subclinical Atherosclerosis and Cardiometabolic Compensation: A Real-World Study in Patients with Type 2 Diabetes
    Patti, Angelo Maria
    Giglio, Rosaria Vincenza
    Allotta, Alberto
    Bruno, Andreina
    Di Bella, Tommaso
    Stoian, Anca Pantea
    Ciaccio, Marcello
    Rizzo, Manfredi
    BIOMEDICINES, 2023, 11 (05)
  • [22] Analysis of the duration and extent of the legacy effect in patients with type 2 diabetes: A real-world longitudinal study
    Takao, Toshiko
    Matsuyama, Yutaka
    Suka, Machi
    Yanagisawa, Hiroyuki
    Kasuga, Masato
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2019, 33 (08) : 516 - 522
  • [23] Older Adults with Type 2 Diabetes Treated with Metformin: AME-MET Study - A Multicentric Real-world Study in Italy
    Elena, Castellano
    Borretta, Giorgio
    Attanasio, Roberto
    Alberto, Boriano
    Agrimi, Daniela
    Argese, Nicola
    Crescenti, Cassandra
    Disoteo, Olga
    Fusco, Alessandra
    Gabellieri, Enrico
    Guglielmi, Rinaldo
    Lisco, Giuseppe
    Lo Pomo, Feliciano
    Nizzoli, Maurizio
    Panico, Annalisa
    Pirali, Barbara
    Salcuni, Antonio Stefano
    Turchi, Federica
    Grimaldi, Franco
    ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS, 2023, 23 (06) : 818 - 825
  • [24] Real-world effectiveness of Semaglutide treatment on weight loss maintenance after weight loss in patients with obesity or overweight and diabetes
    Del Prete, Michela
    Gavazzi, Lidia
    Disoteo, Olga Eugenia
    Vignati, Federico
    Di Sacco, Gianleone
    Muratori, Fabrizio
    EATING AND WEIGHT DISORDERS-STUDIES ON ANOREXIA BULIMIA AND OBESITY, 2025, 30 (01)
  • [25] Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus
    Norris, SL
    Zhang, X
    Avenell, A
    Gregg, E
    Schmid, CH
    Lau, J
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2005, (01):
  • [26] Glycaemic control, weight loss, and use of other antihyperglycaemics in patients with type 2 diabetes initiated on canagliflozin or sitagliptin: a real-world analysis
    Ingham, M.
    Lefebvre, P.
    Pilon, D.
    Lafeuille, M-H.
    Emond, B.
    Kamstra, R.
    Pfeifer, M.
    Duh, M. S.
    Wysham, C.
    DIABETOLOGIA, 2017, 60 : S402 - S403
  • [27] Automated insulin delivery among adults with type 1 diabetes for up to 2 years: a real-world, multicentre study
    Donaldson, Laura E.
    Fourlanos, Spiros
    Vogrin, Sara
    MacIsaac, Richard J.
    Colman, Peter G.
    McAuley, Sybil A.
    INTERNAL MEDICINE JOURNAL, 2024, 54 (01) : 121 - 128
  • [28] The Real-World Study of 2+N System Therapy in Remission of Type 2 Diabetes
    Zeng, Kejing
    Li, Hejun
    Song, Yingying
    Yang, Yin
    Huang, Yali
    Xu, Gugen
    DIABETES, 2023, 72
  • [29] The effectiveness of dapagliflozin and lixisenatide in managing Type 2 diabetes: a real-world observational study
    Duffy, A.
    Smith, C.
    Harrow, C.
    McGowan, N.
    McIntyre, M.
    So, B.
    Jones, C.
    Gonzalez, N.
    DIABETIC MEDICINE, 2016, 33 : 166 - 166
  • [30] IDegAsp treatment in adults with type 2 diabetes in real-world practice: subgroup analysis by dosing frequency
    Kok, A.
    Al-Jaser, S. J.
    Biradar, A.
    Medina, J.
    Mohamed, M.
    Nicodemus, N. A., Jr.
    Olsen, A. H.
    Singh, K. P.
    Fulcher, G.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2022, 186